162 related articles for article (PubMed ID: 9868137)
21. Serum beta 2-microglobulin as a tumour marker in space occupying lesions of central nervous system.
Kumar S; Mathur MD; Anand R; Mehndiratta MM; Anand R
Indian J Pathol Microbiol; 1995 Jan; 38(1):43-7. PubMed ID: 8919468
[TBL] [Abstract][Full Text] [Related]
22. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
23. [Serum beta 2 microglobulin in patients with solid tumors and tumors of the hematopoietic system].
Bosch JA; Ruibal A; Vilardell M; Encabo G; Usón M; Ordi J; Domenech-Torné FM
Rev Esp Oncol; 1984; 31(1):21-5. PubMed ID: 6400138
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
25. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of beta 2-microglobulin assay as a tumor marker].
Ito Y
Nihon Rinsho; 1990 Feb; 48 Suppl():957-9. PubMed ID: 2192180
[No Abstract] [Full Text] [Related]
28. Clinical significance of serum beta 2-microglobulin in leukemia.
Kageyama T; Oyabu H; Tsumoto S
Bull Osaka Med Sch; 1982 Oct; 28(2):134-9. PubMed ID: 6764872
[No Abstract] [Full Text] [Related]
29. Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.
Penz MZ; Fiebiger WC; Valencak JB; Osterreicher C; Ba-Ssalamah A; Formanek M; Brodowic T; Chott A; Raderer M
Anticancer Res; 2001; 21(4B):3049-52. PubMed ID: 11712809
[TBL] [Abstract][Full Text] [Related]
30. Serum alpha 1-microglobulin levels in diseases of the hematopoietic system.
Kageyama T; Ohyabu H
Bull Osaka Med Sch; 1987 Jul; 33(1):71-5. PubMed ID: 2469510
[No Abstract] [Full Text] [Related]
31. Beta 2-microglobulin in haematological malignancies.
Br Med J (Clin Res Ed); 1981 Mar; 282(6269):1013. PubMed ID: 6163499
[No Abstract] [Full Text] [Related]
32. Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma.
Beltran B; Quiñones P; Morales D; Cotrina E; Castillo JJ
Leuk Res; 2011 Mar; 35(3):334-9. PubMed ID: 20828817
[TBL] [Abstract][Full Text] [Related]
33. [Beta 2-microglobulin in the diagnosis of specific involvement of the kidneys in acute leukemias].
Vorob'ev VG; Trunova EM; Borovkov NN
Lab Delo; 1990; (10):31-4. PubMed ID: 1704452
[TBL] [Abstract][Full Text] [Related]
34. [HL-A antigens and malignant hematological diseases].
Jeannet M; Alberto P; Wyss M
Schweiz Med Wochenschr; 1971 Dec; 101(49):1798-800. PubMed ID: 5291103
[No Abstract] [Full Text] [Related]
35. [Clinical significance of serum beta 2-microglobulin as a tumor marker of oral and maxillofacial malignant tumors].
Okitsu M; Shimada J; Hiranuma Y; Shimazaki T; Nakasato M; Katoh K; Inada M; Nagata Y; Eba M; Sakamoto E
Meikai Daigaku Shigaku Zasshi; 1988; 17(2):191-7. PubMed ID: 3078341
[No Abstract] [Full Text] [Related]
36. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
37. [Significance of tumor markers in the treatment of cancer: hematologic malignancy].
Sampi K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3041-5. PubMed ID: 3674891
[TBL] [Abstract][Full Text] [Related]
38. [Importance of determination of serum beta-2-microglobulin levels in patients with Hodgkin's lymphoma].
Raida L; Papajík T; Hlusí A; Faber E; Urbanová R; Heczko M; Jancíková M; Zapletalová J; Komenda S; Indrák K
Vnitr Lek; 2002 Feb; 48(2):91-5. PubMed ID: 11949228
[TBL] [Abstract][Full Text] [Related]
39. Serum beta 2 microglobulin in solitary plasmocytomata.
Avilés A; Huerta J; Zepeda G; Díaz-Maqueo JC
Blood; 1990 Oct; 76(8):1663. PubMed ID: 2207335
[No Abstract] [Full Text] [Related]
40. [Detection of serum sialic acid in three kinds of malignant tumor and its clinical significance].
Liang XH; Liang XM; Yi B
Hunan Yi Ke Da Xue Xue Bao; 2003 Feb; 28(1):65-6. PubMed ID: 12934403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
